GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (NAS:TENX) » Definitions » 12-1 Month Momentum %

Tenax Therapeutics (Tenax Therapeutics) 12-1 Month Momentum % : -87.26% (As of May. 13, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Tenax Therapeutics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-13), Tenax Therapeutics's 12-1 Month Momentum % is -87.26%.

The industry rank for Tenax Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

TENX's 12-1 Month Momentum % is ranked worse than
93.8% of 1484 companies
in the Biotechnology industry
Industry Median: -22.325 vs TENX: -87.26

Competitive Comparison of Tenax Therapeutics's 12-1 Month Momentum %

For the Biotechnology subindustry, Tenax Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenax Therapeutics's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's 12-1 Month Momentum % falls into.



Tenax Therapeutics  (NAS:TENX) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tenax Therapeutics  (NAS:TENX) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Tenax Therapeutics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenax Therapeutics (Tenax Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
Executives
Robyn Hunter director 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Chrisopher Thomas Giordano director, officer: CEO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Armistice Capital, Llc director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. director C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
June Sherie Almenoff director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Declan Doogan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Stuart Rich officer: Chief Medical Officer C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Ronald R Blanck director 2001 WALNUT HILL LANE, IRVING TX 75038
Gerald T Proehl director
James P. Mitchum director C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
John P Kelley officer: Chief Executive Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502

Tenax Therapeutics (Tenax Therapeutics) Headlines

From GuruFocus

Tenax Therapeutics Announces Reverse Stock Split

By Stock market mentor Stock market mentor 01-04-2023

Tenax Therapeutics, Inc. Expands Board of Directors

By Business Wire Business Wire 03-02-2021